HOME >> BIOLOGY >> NEWS
Cancer drug target Chk1 may also be source of drug resistance

(September 1, 2005, La Jolla, CA) A study published by The Burnham Institute in the September edition of Molecular Cell reports that a cell-cycle checkpoint protein, known to be activated by an important class of anticancer drugs, may play crucial roles in both the hampering of therapeutic actions and aiding cancer cells to "recover" and start dividing again after treatment with these drugs. The study is expected to help academic researchers and biotechnology and pharmaceutical companies design drugs that combat cancer using this checkpoint protein, but with fewer side effects.

Robert Abraham, Ph.D., former director of The Burnham Institute's Cancer Center and now vice president for oncology research at Wyeth Pharmaceuticals, together with his colleagues, found that the Chk1 protein responds with cell-survival activity to stressful conditions induced by hypoxia and certain anticancer drugs. Furthermore these same conditions target Chk1 for eventual destruction. Ironically, stimulation of Chk1 triggers certain repair responses that fight cancer while the simultaneous degradation of Chk1 can allow cancer cells to escape drug-induced death and resume progressive tumor growth.

The study suggests the Chk1 protein is critical for ensuring the repair of mutations and other errors in DNA replication before they can alter the function of a cell. If not repaired, these errors can kill the cell when it attempts to divide and proliferate. In cancer cells, Chk1 is responds as a natural defense to the therapeutic damage done by radiation and chemotherapy and attempts to effect repair to DNA damage caused by the cancer therapy, thus makes the drug therapy less effective.

The researchers also found that the chemotherapy agent campthothecin (CPT), a clinically important anticancer agent, reduced the activity of the Chk1 protein. "These findings lend strong support to the idea that inactivation of Chk1 contributes to the antitumor activity of CPT by allowing
'"/>

Contact: Nancy Beddingfield
nbeddingfield@burnham.org
858-646-3146
Burnham Institute
2-Sep-2005


Page: 1 2

Related biology news :

1. Journalists can register now for ECCO 14 -- the European Cancer Conference
2. Cancer cures could work for canines and humans
3. The Cancer Genome Atlas awards funds for technology development
4. Cancer research specialist and HSPH professor awarded Medal of Honor from WHO cancer agency
5. Cancer stem cells similar to normal stem cells can thwart anti-cancer agents
6. Cancer stem cells can go it alone
7. Cancer drug enhances long-term memory
8. Cancer cells reprogram energy needs to grow and spread, study suggests
9. Cancer scientists create human leukemia process to map how disease begins, progresses
10. Cancer tip -- Nanoparticles can damage DNA, increase cancer risk
11. Other highlights from the April 18 Journal of the National Cancer Institute

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/26/2020)... (PRWEB) , ... August 24, 2020 , ... ... for the treatment of chronic inflammatory and fibrotic diseases, today announced that Dr. ... President of Drug Discovery. , Dr. Canan previously served as Executive Director of ...
(Date:8/23/2020)... WOODLANDS, Texas (PRWEB) , ... August 21, 2020 ... ... from Rigaku Corporation has been published and is now available on ... single crystal X-ray diffraction—serves the X-ray analysis community, presenting current news and crystallographic ...
(Date:8/21/2020)... Virginia (PRWEB) , ... August 20, 2020 , ... ... today that Hassan Movahhed , a Clinical Operations executive with expertise in ... management, has joined the firm as an Expert Consultant. Throughout his career, Mr. ...
Breaking Biology News(10 mins):
(Date:8/12/2020)... ... August 11, 2020 , ... The FSHD ... Facioscapulohumeral Muscular Dystrophy Clinical Trial Research Network (FSHD CTRN), with consideration ... is a consortium of academic research centers in the United States and Europe ...
(Date:8/7/2020)... ... August 06, 2020 , ... ... announces it has closed on the purchase of greenfield for a new, expanded ... and includes over 21 acres in the initial acquisition, with an option to ...
(Date:7/31/2020)... ... July 29, 2020 , ... R3 Stem Cell International is now ... With 50 million stem cells total, patients may choose which extremities they would like ... arthritic joints (BMC Musculoskelet Disord. 2016). At R3 International, umbilical cord tissue is obtained ...
(Date:7/31/2020)... SHREWSBURY, Mass. (PRWEB) , ... July 29, 2020 ... ... clad wire that can combine up to three different materials for use with ... can combine up to three materials to meet specific design requirements, performance, and ...
Breaking Biology Technology:
Cached News: